Camp4 Therapeutics Corp
CAMP- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001736730
In the last 90 days, Camp4 Therapeutics Corp insiders filed 5 open-market purchases and 4 sales; 61 institutions reported holding it in 13F filings for Q2 2026, worth $182.4M in total; no superinvestor holds it.
Key figures
- Insider buysLast 90 days, $99.1K in total
- 5
- Insider sellsLast 90 days, $2.50M in total
- 4
- 13F holdersQ2 2026, +16 vs. previous quarter
- 61
- 13F valueReported value at the end of Q2 2026
- $182.4M
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Superinvestors holding CAMP, Q2 2026
No superinvestor reported holding CAMP at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by Camp4 Therapeutics Corp insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Sep 2, 2026 (view filing)7:50 PM ET | Aug 31 | 2 days | Gold KellyChief Financial Officer | PPurchase | +10.0K | $3.96 | +$39.6K | New position10.0K after | |
| Aug 31, 2026 (view filing)5:05 PM ET | Aug 27 | 4 days | Schwab Andrew J.Director | SSale | −400.0K | $4.04 | −$1.62M | −16.4%2.03M after | |
| Aug 26, 2026 (view filing)4:57 PM ET | Aug 24 | 2 days | Schwab Andrew J.Director | SSale | −10 | $4.50 | −$45 | 0.0%2.43M after | |
| Aug 21, 2026 (view filing)4:59 PM ET | Aug 19-21 | 2 days | Schwab Andrew J.Director | SSale | −191.9K | $4.59 | −$879.7K | −7.3%2.43M after | 3 lots |
| Aug 19, 2026 (view filing)8:46 PM ET | Aug 19 | Same day | Tardiff DanielChief Scientific Officer | SSale | −1.74K | $4.76 | −$8.27K | −100.0%0 after | |
| Aug 5, 2026 (view filing)5:39 PM ET | Aug 3 | 2 days | Parmar Kush and 6 others10% Owner | PPurchase | +3.18M | $1.53 | +$4.86M | –3.18M after | Derivative |
| Aug 5, 2026 (view filing)5:09 PM ET | Aug 3 | 2 days | Young Richard ADirector | PPurchase | +16.4K | $1.65 | +$27.0K | +9.6%186.4K after | |
| Aug 5, 2026 (view filing)5:08 PM ET | Aug 3 | 2 days | Maricich YuriChief Medical Officer | PPurchase | +6.55K | $1.65 | +$10.8K | +108.1%12.6K after | |
| Aug 5, 2026 (view filing)5:08 PM ET | Aug 3 | 2 days | Gold KellyChief Financial Officer | PPurchase | +6.55K | $1.65 | +$10.8K | +9.7%74.4K after | |
| Aug 5, 2026 (view filing)5:07 PM ET | Aug 3 | 2 days | Mandel-Brehm JoshChief Executive Officer | PPurchase | +6.55K | $1.65 | +$10.8K | +2.4%285.0K after |
Top 10 13F holders, Q2 2026
The largest institutional positions in Camp4 Therapeutics Corp at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Jupiter Topco LLC | 6,307,636 | $27.6M | 0.01% | +6,307,636 | New |
| 5AM Venture Management, LLC | 5,869,091 | $25.6M | 8.91% | 00.0% | Unchanged |
| FMR LLC | 4,904,339 | $21.4M | 0.00% | −29,093−0.6% | Reduced |
| Vivo Capital, LLC | 4,246,568 | $18.6M | 1.69% | 00.0% | Unchanged |
| Balyasny Asset Management LLC | 2,575,724 | $11.3M | 0.02% | −56,713−2.2% | Reduced |
| AH Capital Management, L.L.C. | 2,125,339 | $9.29M | 0.07% | 00.0% | Unchanged |
| Adage Capital Partners GP, L.L.C. | 1,960,784 | $8.57M | 0.01% | 00.0% | Unchanged |
| Trails Edge Capital Partners, LP | 1,932,937 | $8.45M | 1.34% | −6,626−0.3% | Reduced |
| BlackRock, Inc. | 1,644,134 | $7.18M | 0.00% | +1,187,763+260.3% | Added |
| Vanguard Capital Management LLC | 1,533,489 | $6.70M | 0.00% | −1,279−0.1% | Reduced |